Form 4 for BIOA BioAge Labs, Inc.
Accepted 2025-12-05 00:00:00 ET · period of report 2025-12-04 · accession 0001210905-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-05 | 2025-12-04 | BIOA | RUBIN PAUL D | Chief Medical Off | M - OptEx | $4.11 | +68.9K | 68.9K | New | +$283.2K |
| D | 2025-12-05 | 2025-12-04 | BIOA | RUBIN PAUL D | Chief Medical Off | S - Sale+OE | $10.19 | -68.9K | 0 | -100% | -$702.1K |
| D | 2025-12-05 | 2025-12-04 | BIOA | RUBIN PAUL D | Chief Medical Off | M - OptEx | $0.00 | -68.9K | 21.7K | -76% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-04 | M | A | 68,897 | $4.11 | 68,897 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-04 | S | D | 68,897 | $10.19 | 0 | D | — | — | (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.96 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-12-04 | M | D | 68,897 | $0.00 | 21,736 | D | $4.11 · — to 2030-06-30 | 68,897 Common Stock | (F3) This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024. |